Pacira Pharma (PCRX) Tops Q3 EPS by 7c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does